Biotech RadarJobs updated

COMPANY

Extend Biosciences Inc.

HQ: Newton, MA source · extendbio.com ↗

Clinical Phase 2

Also known as Extend Biosciences · 5 sources

Location: Newton, MA · source · Oct 15, 2026

Profile checked Oct 10, 2026

Keywords: Hypoparathyroidism Safety Issues EXT608

2Trials (company is sponsor)

Timeline

  1. Grant Government grant: $839,497 (total, as published), announced Sep 15, 2026. Agency: DoD. Source: government award database. source ↗
  2. Grant Government grant — SBIR: $999,615 (annual award, as published), announced Aug 8, 2025. Agency: NIH/NIDDK. Source: government award database. source ↗
  3. Grant Government grant — NIH R01: $899,808 (annual award, as published), announced Jun 24, 2025. Agency: NIH/FDA. Source: government award database. source ↗
  4. Trial start 2: A Phase 2 Trial Investigating the Safety, Tolerability and Efficacy of EXT608 in Adults With Hypoparathyroidism source ↗
  5. Trial start 1: A Phase 1 Study of EXT608 in Healthy Adults source ↗

Upcoming milestones

Estimated primary completion per ClinicalTrials.gov. Dates move.

Funding

Last 2 years.

Clinical trials (lead sponsor) 2

RecordTitlePhaseStatusStartPrimary completion
NCT06988670A Phase 2 Trial Investigating the Safety, Tolerability and Efficacy of EXT608 in Adults With Hypoparathyroidism2RecruitingMay 5, 20252027-05 (estimated)
NCT05408663A Phase 1 Study of EXT608 in Healthy Adults1CompletedJul 21, 2022Jun 13, 2023 (actual)
Feedback